Across TCGA pan-cancer cohorts, XPNPEP3 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated XPNPEP3 data layer compared with 26 for mass-spec protein and 6 for mass-spec protein.
The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher XPNPEP3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated XPNPEP3 expression acts as an unfavorable survival marker.
BLCA, SKCM, and PRAD are the cancer types where XPNPEP3 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.